At a glance
ClinicalIndex Comparison Record- ✓Histologically proven glioblastoma multiforme with central pathology review
- ✓Tumor specimen obtained at surgery adequate for vaccination
- ✓Age 18 years or older
- ✓Karnofsky Performance Status 60% or greater
- ✕Invasive malignancies in the past 5 years
- ✕History of rheumatologic or autoimmune disease
- ✕Active autoimmune disease
- ✕Pregnancy or unwillingness to use acceptable birth control
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Feasibility Study of Adjuvant Intra-Nodal Autologous Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme
In Brief
A Phase 2 clinical trial evaluating Autologous Dendritic Cell, Temozolomide, and 2 other interventions for Glioblastoma Multiforme. Completed, enrolled 11 participants across 1 site.
Detailed Summary
Adult patients who have surgical resection of newly diagnosed glioblastoma multiforme will be treated with radiotherapy/chemotherapy followed by dendritic cell vaccine. Chemotherapy will be administered after three vaccinations for one year or until progression of disease.
Study Details
Timeline
Interventions
Vaccine given by cervical lymph node injection 3 times every other week
Radiotherapy (RT) with concurrent temozolomide (TMZ) for 6 weeks before vaccine is SOC
RT is standard of care (SOC) post surgery
Vaccine given cervical lymphnode injection 3 times every other week